Aurobindo Pharma Limited (NSE:AUROPHARMA)

Aurobindo Pharma Ratios and Metrics

Market cap in millions INR. Fiscal year is April - March.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Nov 18, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Market Capitalization	719,787	674,020	637,941	303,575	391,729	516,388
Market Cap Growth	-12.25%	5.66%	110.14%	-22.50%	-24.14%	113.31%
Enterprise Value	708,736	689,676	632,994	283,996	394,408	532,915
Last Close Price	1239.30	1156.16	1084.68	513.88	653.35	855.63
PE Ratio	21.03	19.34	20.11	15.75	14.79	9.68
Forward PE	18.01	15.91	17.77	12.19	12.83	14.88
PS Ratio	2.21	2.13	2.20	1.22	1.67	2.08
PB Ratio	2.05	2.07	2.14	1.13	1.59	2.36
P/TBV Ratio	2.35	2.36	2.46	1.31	1.85	2.73
P/FCF Ratio	19.87	34.45	-	-	13.22	27.31
P/OCF Ratio	11.69	17.17	26.20	12.72	7.81	15.51
PEG Ratio	1.72	1.36	0.78	1.63	2.09	1.35
EV/Sales Ratio	2.18	2.17	2.18	1.14	1.68	2.15
EV/EBITDA Ratio	10.78	10.72	10.98	7.81	9.15	9.88
EV/EBIT Ratio	14.15	13.83	14.41	11.31	11.93	11.97
EV/FCF Ratio	19.56	35.25	-	-	13.31	28.18
Debt / Equity Ratio	0.22	0.25	0.22	0.20	0.12	0.24
Debt / EBITDA Ratio	1.18	1.27	1.14	1.43	0.65	0.97
Debt / FCF Ratio	2.15	4.22	-	-	0.96	2.82
Asset Turnover	0.65	0.67	0.68	0.67	0.69	0.79
Inventory Turnover	1.27	1.33	1.42	1.45	1.26	1.22
Quick Ratio	0.95	0.99	0.96	0.98	1.10	0.90
Current Ratio	1.85	1.85	1.98	1.88	2.22	1.86
Return on Equity (ROE)	10.38%	11.15%	11.18%	7.50%	11.39%	27.53%
Return on Assets (ROA)	6.25%	6.57%	6.46%	4.25%	6.10%	8.87%
Return on Capital (ROIC)	7.66%	8.05%	8.00%	5.27%	7.56%	11.13%
Return on Capital Employed (ROCE)	13.60%	14.20%	13.40%	8.80%	12.80%	19.20%
Earnings Yield	4.75%	5.17%	4.97%	6.35%	6.76%	10.33%
FCF Yield	5.03%	2.90%	-0.54%	-0.06%	7.56%	3.66%
Dividend Yield	0.65%	-	0.41%	0.58%	1.38%	0.47%
Payout Ratio	6.80%	0.03%	8.31%	22.80%	9.96%	4.39%
Buyback Yield / Dilution	0.58%	0.52%	-	-	-	-
Total Shareholder Return	1.23%	0.52%	0.41%	0.58%	1.38%	0.47%

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.